This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Zhong, J.-q. Articles by Dorian, P. Search for Related Content PubMed PubMed Citation Articles by Zhong, J.-q. Articles by Dorian, P. Social Bookmarking                         What's this?

Effects of Rotigaptide, a Gap Junction Modifier, on Defibrillation Energy and Resuscitation From Cardiac Arrest in Rabbits

Department of Medicine, University of Toronto and Division of Cardiology, St. Michael's Hospital, Toronto

Gabriel Laurent, MD

Department of Medicine, University of Toronto and Division of Cardiology, St. Michael's Hospital, Toronto

Petsy Pui-Sze So, BSc

Department of Medicine, University of Toronto and Division of Cardiology, St. Michael's Hospital, Toronto

Xudong Hu, MD

Department of Medicine, University of Toronto and Division of Cardiology, St. Michael's Hospital, Toronto

James K. Hennan, PhD

Wyeth Research, Philadelphia, Pennsylvania

Paul Dorian, MD, MS

Department of Medicine, University of Toronto and Division of Cardiology, St. Michael's Hospital, Toronto, dorianp{at}smh.toronto.on.ca

The gap junction modifier Rotigaptide (ZP123), which promotes cellular coupling, was hypothesized to decrease defibrillation thresholds during prolonged ventricular fibrillation (VF). Thirty-two New Zealand white rabbits were randomized to receive saline (control, n = 16) or Rotigaptide (n = 16). Following 4 min of untreated VF, biphasic defibrillation shocks were applied through chest wall patches, starting either at 300 volts (V) (n = 16) or 500 V (n = 16), with 200 V increasing steps to 900 V in case of shock failure. Rotigaptide significantly decreased defibrillation voltage requirements (average cumulative voltage of all shocks: 1206 ± 709 V in control group vs. 844 ± 546 V in treated group, P = .002). Rotigaptide had no effect on heart rate, QRS duration, QT interval, ventricular effective refractory period, monophasic action potential duration or on connexin 43 density using immunofluorescence. Rotigaptide improves the ability to defibrillate after untreated VF.

Key Words: gap junctions • ventricular fibrillation • defibrillation • connexin 43

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 12, No. 1, 69-77 (2007)
DOI: 10.1177/1074248406298021


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?